UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study

Breast cancer research and treatment, 2019-02, Vol.174 (1), p.187-196

2019

Volltextzugriff (PDF)

Use of primary and secondary pegfilgrastim prophylaxis for reducing incidence of neutropenia: Findings from a large study in German clinical practice (PROTECT)

Annals of oncology, 2018-10, Vol.29, p.viii609-viii609

2018

Volltextzugriff (PDF)

Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study

Breast cancer research and treatment, 2019-06, Vol.175 (2), p.389-399

2019

Volltextzugriff (PDF)

1570 The compatibility of biosimilar filgrastim under cytotoxic chemotherapy in the treatment of malignant diseases: VENICE study

European journal of cancer (1990), 2015-09, Vol.51, p.S227-S227

2015

Volltextzugriff (PDF)

SANDOZ RITUXIMAB FOR TREATMENT OF DIFFUSE LARGE B‐CELL LYMPHOMA: INTERIM SAFETY RESULTS OF THE NON‐INTERVENTIONAL, OBSERVATIONAL, MULTICENTER, OPEN‐LABEL REFLECT STUDY

Hematological oncology, 2019-06, Vol.37 (S2), p.444-445

2019

Volltextzugriff (PDF)

OHERA: A real world study of cardiac events in > 3700 patients with her2-positive early breast cancer treated with trastuzumab: Final analysis

ANNALS OF ONCOLOGY, 2017-09, Vol.28, p.v52-v52

2017

Volltextzugriff (PDF)

The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer

Current medical research and opinion, 2016-07, Vol.32 (7), p.1217-1224

2016

Volltextzugriff (PDF)

Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial

British journal of cancer, 2009-01, Vol.100 (1), p.44-49

2009

Volltextzugriff (PDF)

Typische Krisen und Bedürfnisse von Patienten mit COPD oder Lungenkrebs im letzten Lebensjahr - eine Literaturübersicht

Zeitschrift für Palliativmedizin, 2012-05, Vol.13 (3), p.134-141

2012

Volltextzugriff (PDF)

Pegylated liposomal doxorubicin (CAELYX®) in patients with advanced ovarian cancer: results of a German multicenter observational study

Cancer chemotherapy and pharmacology, 2009-07, Vol.64 (3), p.585-591

2009

Volltextzugriff (PDF)

3630 POSTER Development of 46 Quality Indicators for Cancer Care in Office-based Medical Oncology

European journal of cancer (1990), 2011, Vol.47, p.S268-S268

2011

Volltextzugriff (PDF)

Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

The New England journal of medicine, 2009-02, Vol.360 (7), p.679-691

2009

Volltextzugriff (PDF)

A fatal case of AIDS-defining meningoencephalitis by C. neoformans, sensitive to antifungal therapy

European journal of medical research, 2010-11, Vol.15 (11), p.504-506, Article 504

2010

Volltextzugriff (PDF)

1701PUse of primary and secondary pegfilgrastim prophylaxis for reducing incidence of neutropenia: Findings from a large study in German clinical practice (PROTECT)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Home administration of filgrastim (Nivestim™) in primary prophylaxis of chemotherapy-induced febrile neutropenia

Patient preference and adherence, 2018-01, Vol.12, p.2179-2186

2018

Volltextzugriff (PDF)

Chemotherapeutische und zielgerichtete Behandlung bei älteren Patientinnen mit Mammakarzinom - Daten aus dem ELDERLY Projekt

Senologie (Stuttgart), 2013, Vol.10 (2)

2013

Volltextzugriff (PDF)

WSG-BCIST mit PAM50 – Prospektive Beobachtungsstudie des klinischen Outcomes für den Prosigna® Technologie Breast Cancer Intrinsic Subtype Test

Geburtshilfe und Frauenheilkunde, 2014, Vol.74 (S 01)

2014

Volltextzugriff (PDF)

PS1074 SANDOZ RITUXIMAB FOR THE TREATMENT OF DIFFUSE LARGE B‐CELL LYMPHOMA: INTERIM SAFETY RESULTS OF THE PROSPECTIVE NON‐INTERVENTIONAL, OBSERVATIONAL, MULTICENTER, OPEN‐LABEL REFLECT STUDY

HemaSphere, 2019-06, Vol.3 (S1), p.486-487

2019

Volltextzugriff (PDF)

WSG-BCIST mit PAM50 – Prospektive Beobachtungsstudie des klinischen Outcomes für den Prosigna® Technologie Breast Cancer Intrinsic Subtype Test

Senologie (Stuttgart), 2014, Vol.11 (2)

2014

Volltextzugriff (PDF)

Identification of 46 quality indicators for cancer care in office-based oncology practices in Germany

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e16514-e16514

2011

Volltextzugriff (PDF)

Safety and cost effectiveness of a 10 x 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 x 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia

Blood, 1998-05, Vol.91 (10), p.3601

1998

Volltextzugriff (PDF)

A randomized phase III study evaluating pegylated liposomal doxorubicin (PLD) versus capecitabine (CAP) as first-line therapy for metastatic breast cancer (MBC): Results of the PELICAN study

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.1022-1022

2010

Volltextzugriff (PDF)

Interim safety analysis of the randomized phase III PELICAN trial evaluating pegylated liposomal doxorubicin (PLD) versus capecitabine as first-line therapy for metastatic breast cancer

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.1118-1118

2009

Volltextzugriff (PDF)

The situation of teaching nursing informatics in nursing education

Studies in health technology and informatics, 2000, Vol.57, p.77

2000

Volltextzugriff (PDF)

How is the clinical practice? Pegylated liposomal doxorubicin in the therapy of patients with recurrent ovarian cancer: Results of a German observational study

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.16552-16552

2008

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieCancer Research

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(48)
Tagungsberichte
(8)

Sprache

Englisch
(41)
Deutsch
(13)
Polnisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(22)
Humans
(20)
Life Sciences & Biomedicine
(19)
Female
(11)
Biological And Medical Sciences
(10)
Medical Sciences
(9)
Middle Aged
(9)
Adult
(8)
Oncology
(6)
Aged
(4)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(4)
Breast Cancer
(4)
General & Internal Medicine
(4)
Male
(4)
Medicine, General & Internal
(4)
Pharmacology. Drug Treatments
(4)
Tumors
(4)
Animals
(3)
Antineoplastic Agents
(3)
Cancer Research
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study

Use of primary and secondary pegfilgrastim prophylaxis for reducing incidence of neutropenia: Findings from a large study in German clinical practice (PROTECT)

Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study

1570 The compatibility of biosimilar filgrastim under cytotoxic chemotherapy in the treatment of malignant diseases: VENICE study

SANDOZ RITUXIMAB FOR TREATMENT OF DIFFUSE LARGE B‐CELL LYMPHOMA: INTERIM SAFETY RESULTS OF THE NON‐INTERVENTIONAL, OBSERVATIONAL, MULTICENTER, OPEN‐LABEL REFLECT STUDY

OHERA: A real world study of cardiac events in > 3700 patients with her2-positive early breast cancer treated with trastuzumab: Final analysis

The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer

Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial

Typische Krisen und Bedürfnisse von Patienten mit COPD oder Lungenkrebs im letzten Lebensjahr - eine Literaturübersicht

Pegylated liposomal doxorubicin (CAELYX®) in patients with advanced ovarian cancer: results of a German multicenter observational study

3630 POSTER Development of 46 Quality Indicators for Cancer Care in Office-based Medical Oncology

Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

A fatal case of AIDS-defining meningoencephalitis by C. neoformans, sensitive to antifungal therapy

1701PUse of primary and secondary pegfilgrastim prophylaxis for reducing incidence of neutropenia: Findings from a large study in German clinical practice (PROTECT)

Home administration of filgrastim (Nivestim™) in primary prophylaxis of chemotherapy-induced febrile neutropenia

Chemotherapeutische und zielgerichtete Behandlung bei älteren Patientinnen mit Mammakarzinom - Daten aus dem ELDERLY Projekt

WSG-BCIST mit PAM50 – Prospektive Beobachtungsstudie des klinischen Outcomes für den Prosigna® Technologie Breast Cancer Intrinsic Subtype Test

PS1074 SANDOZ RITUXIMAB FOR THE TREATMENT OF DIFFUSE LARGE B‐CELL LYMPHOMA: INTERIM SAFETY RESULTS OF THE PROSPECTIVE NON‐INTERVENTIONAL, OBSERVATIONAL, MULTICENTER, OPEN‐LABEL REFLECT STUDY

WSG-BCIST mit PAM50 – Prospektive Beobachtungsstudie des klinischen Outcomes für den Prosigna® Technologie Breast Cancer Intrinsic Subtype Test

Identification of 46 quality indicators for cancer care in office-based oncology practices in Germany

Safety and cost effectiveness of a 10 x 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 x 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia

A randomized phase III study evaluating pegylated liposomal doxorubicin (PLD) versus capecitabine (CAP) as first-line therapy for metastatic breast cancer (MBC): Results of the PELICAN study

Interim safety analysis of the randomized phase III PELICAN trial evaluating pegylated liposomal doxorubicin (PLD) versus capecitabine as first-line therapy for metastatic breast cancer

The situation of teaching nursing informatics in nursing education

How is the clinical practice? Pegylated liposomal doxorubicin in the therapy of patients with recurrent ovarian cancer: Results of a German observational study

Aktive Filter

Suchergebnisse filtern